APA (7th ed.) Citation

Chim, C. S., Kumar, S., Wong, V. K. C., Ngai, C., & Kwong, Y. L. (2021). 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Hematology, 26(1), 652. https://doi.org/10.1080/16078454.2021.1965737

Chicago Style (17th ed.) Citation

Chim, Chor Sang, Shaji Kumar, Vincent Kai Chung Wong, Cheong Ngai, and Yok Lam Kwong. "3-weekly Daratumumab-lenalidomide/pomalidomide-dexamethasone Is Highly Effective in Relapsed and Refractory Multiple Myeloma." Hematology 26, no. 1 (2021): 652. https://doi.org/10.1080/16078454.2021.1965737.

MLA (9th ed.) Citation

Chim, Chor Sang, et al. "3-weekly Daratumumab-lenalidomide/pomalidomide-dexamethasone Is Highly Effective in Relapsed and Refractory Multiple Myeloma." Hematology, vol. 26, no. 1, 2021, p. 652, https://doi.org/10.1080/16078454.2021.1965737.